SLC5A2 and Right ventricular hypertrophy: The results of basic experimental studies suggest that SGLT2-i may improve the prognosis of PH in PH rats by lowering systemic blood pressure, reducing mPAP, RVSP, reducing right ventricular hypertrophy and fibrosis, and alleviating pulmonary artery myositis in rats (8–12).